Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00299804 in Metastatic or Recurrent Esophageal Squamous Cell Carcinoma
NCT01608022Phase 2Completed
- Sponsor
- Yonsei University
- Start
- Jul 2012
- Primary completion
- Apr 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dacomitinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Yonsei University. Started Jul 2012; status: completed.
02
Drugs
dacomitinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT01608022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01608022.